SEATTLE, Dec. 06, 2025 (GLOBE NEWSWIRE) — Adaptive Biotechnologies Corporation (Nasdaq: ADPT), a commercial stage biotechnology company that aims to translate the genetics of the adaptive immune system into clinical products to diagnose and treat disease, announced growing interventional use of its clonoSEQ® test among the 90 abstracts featuring clonoSEQ data at the 67th American Society of Hematology (ASH) Annual Meeting and Exposition, taking place Dec. 6–9, 2025, in Orlando. Notably, 17 abstracts utilizing Adaptive’s clonoSEQ® test exemplify how next-generation sequencing-based measurable residual disease (MRD) status is guiding clinical actions to improve blood cancer patient care. Practice-changing data from the phase II EndRAD study support the use of NGS MRD status prior to allogeneic hematopoietic cell transplantation (HCT)...

Ficerafusp alfa 750mg QW in combination with pembrolizumab demonstrates consistent overall response rate and safety profile comparable to 1500mg QW dose, further derisking pivotal FORTIFI-HN01 study interim analysis Totality of data demonstrates that greater TGF-β inhibition, observed at 1500mg of ficerafusp alfa, drives deeper tumor responses that translate to more durable outcomes for patients Pivotal FORTIFI-HN01 optimal dose declaration expected in first quarter 2026 Company to host conference call and webcast today at 9:00 a.m. ET BOSTON, Dec. 06, 2025 (GLOBE NEWSWIRE) —  Bicara Therapeutics Inc. (Nasdaq: BCAX), a clinical-stage biopharmaceutical company committed to bringing transformative bifunctional therapies to patients with solid tumors, today presented preliminary data from a Phase 1b expansion cohort evaluating 750...

Updated Data from 31 Adult and Adolescent SCD Patients Treated with risto-cel (Formerly BEAM-101) Show Mean Hemoglobin F (HbF) Induction of >60%, Hemoglobin S (HbS) Reduction to

TUS+VEN+AZA triplet frontline therapy demonstrates high rates of efficacy and MRD-negative remissions in newly diagnosed AML patients with diverse mutationsSafety continues to be a notable hallmark of TUS-based therapies100% response rate (CR/CRh) at the two higher dose levels (80 and 120 mg TUS dose)CR/CRh observed in FLT3 wildtype subjects, representing ~70% of AML patientsCR/CRh observed in AML with TP53/complex karyotype, RAS, and MDS-related mutationsSAN DIEGO and TORONTO, Dec. 06, 2025 (GLOBE NEWSWIRE) — Aptose Biosciences Inc. (“Aptose” or the “Company”) (NASDAQ: APTO, TSX: APS), a clinical-stage precision oncology company developing highly differentiated targeted agents to treat hematologic malignancies, today featured clinical data for its lead compound tuspetinib (TUS) combined with standard dosing of venetoclax...

Demonstrated meaningful overall anemia responses across all patient subgroups, regardless of baseline transfusion status  Anemia response was seen independent of concomitant JAK inhibitor therapy useWATERTOWN, Mass., Dec. 06, 2025 (GLOBE NEWSWIRE) — Disc Medicine, Inc. (NASDAQ:IRON), a clinical-stage biopharmaceutical company focused on the discovery, development, and commercialization of novel treatments for patients suffering from serious hematologic diseases, today presented positive initial data from the RALLY-MF Phase 2 trial of DISC-0974 in anemia of MF at the ASH Annual Meeting in Orlando, FL. The data demonstrated that treatment with DISC-0974 resulted in substantial reductions in hepcidin and increases in iron levels translating to positive impact on clinically meaningful measures of anemia across a broad range of patient...

– Data support initiation of a combination cohort in the ongoing Phase 1 clinical trial to evaluate ARV-393 plus glofitamab as a chemotherapy-free combination approach in diffuse large B-cell lymphoma (DLBCL); initiation expected in 2026 – NEW HAVEN, Conn., Dec. 06, 2025 (GLOBE NEWSWIRE) — Arvinas, Inc. (Nasdaq: ARVN), a clinical-stage biotechnology company creating a new class of drugs based on targeted protein degradation, today announced preclinical data for ARV-393, a PROTAC BCL6 degrader, in combination with glofitamab, a CD20×CD3 bispecific antibody, presented in a poster at the 67th American Society of Hematology (ASH®) Annual Meeting and Exposition, held December 6–9, 2025, in Orlando, Florida. In a humanized high-grade B-cell lymphoma (HGBCL) cell line–derived xenograft (CDX) model, the combination of ARV-393 and glofitamab...

Oslo/Cape Town, 06 December 2025: Scatec ASA, a leading renewable energy provider, has started commercial operation of the 273 MW Grootfontein solar power plant in South Africa, which will generate predictable revenues from a 20-year power purchase agreement (PPA). “We are proud to commence commercial operations at Grootfontein, reinforcing our strong track record in South Africa. This project builds on our commitment to deliver clean, reliable energy while creating long-term value for local communities and partners. We thank our stakeholders for their continued collaboration and look forward to continuing our support of the energy transition in South Africa,” says Scatec CEO, Terje Pilskog. “Bringing the Grootfontein plant into operation is an important milestone for Scatec and our partners. As our first project in the Western Cape, and...

Long-term OS follow-up analysis of JUPITER-02 demonstrates significantly better and clinically meaningful improvement with toripalimab plus chemotherapy as 1st-line treatment for R/M NPC, achieving mOS of 64.8 months and a 5-year OS rate of 52.3%. Torpalimab plus chemotherapy has been approved in over 40 countries, representing the new standard of care for the 1st line treatment of R/M NPC. The final OS analysis of JUPITER-06 confirms the sustained survival benefit with toripalimab plus chemotherapy in advanced ESCC, showing a mOS of 17.7 months and a 3-year OS rate of 29.7%. Results from JUPITER-02 and JUPITER-06 were orally presented at ESMO Asia 2025.SHANGHAI, Dec. 05, 2025 (GLOBE NEWSWIRE) — Shanghai Junshi Biosciences Co., Ltd (Junshi Biosciences, HKEX: 1877; SSE: 688180), a leading innovation-driven biopharmaceutical company...

Highly differentiated 1L preliminary systemic activity of 67% ORR and 100% intracranial ORR (by BICR-RANO), including in patients with active brain metastases 45% ORR in 2L patients exceeds competitor benchmarks Competitive safety profile, with no significant off-target toxicity and manageable on-target toxicity, resulting in low discontinuation rate Enrollment and follow-up continue in 1L patients at selected dose of 80 mg once daily, with next update expected mid-2026 ahead of initiation of potential Phase 3 trial Company to host a conference call and webcast on Saturday, December 6, 2025, at 8:00 pm ET SOUTH SAN FRANCISCO, Calif. and SAN DIEGO, Dec. 05, 2025 (GLOBE NEWSWIRE) — ORIC Pharmaceuticals, Inc. (Nasdaq: ORIC), a clinical stage oncology company focused on developing treatments that address mechanisms of therapeutic...

// Not for distribution to the United States newswire services or for dissemination in the United States // VANCOUVER, British Columbia, Dec. 05, 2025 (GLOBE NEWSWIRE) — Copper Quest Exploration Inc. (CSE: CQX; FRA: 3MX) (“Copper Quest” or the “Company”) is pleased to announce that, further to its news release dated December 1, 2025, it has issued an aggregate of 10,142,104 flow-through shares of the Company (the “FT Shares“, and each, a “FT Share“) at a price of $0.19 per FT Share for aggregate gross proceeds of $1,927,000 in connection with its previously announced fully subscribed non-brokered private placement (the “Private Placement“). Each FT Share constitutes a “flow-through share” within the meaning of the Income Tax Act (Canada) (the “Tax Act“) and the gross proceeds of the...